Cagrilintide Research for Obesity
An evidence-based overview of research examining Cagrilintide in the context of obesity. This page synthesizes findings from peer-reviewed literature.
Research Summary
Cagrilintide has shown significant weight loss efficacy in Phase 2 clinical trials. Monotherapy achieved -10.8% weight loss at 26 weeks. When combined with semaglutide (CagriSema), Phase 2 data showed -15.6% to -17.1% weight loss. Phase 3 REDEFINE trials are ongoing with results expected in 2025.
Referenced Studies
Click any PMID to view the full study on PubMed.
Other Peptides Studied for Obesity
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. Cagrilintide may have regulatory approval for some indications but should only be used under qualified medical supervision. Always consult a healthcare provider before making health decisions.